THERAPEUTIC DRUGS FOR GASTROINTESTINAL CANCER MARKET ANALYSIS BY TYPE, APPLICATION, REGIONS AND COMPANIES FORECAST
2024-11-27 | Pages: 200+ | Report ID: BYR-132387 | Pharmaceuticals and Medical
Historical data: 2017 - 2023
Forecast period: 2025 - 2031
Quantitative units: Revenue in USD million and CAGR from 2025 to 2031
Report coverage: Revenue forecast, company ranking, competitive landscape, growth factors, and trends
Therapeutic Drugs For Gastrointestinal Cancer Market
1.1 SCOPE OF THE REPORT
1.2 MARKET SEGMENT ANALYSIS
1.3 REGULATORY SCENARIO BY REGION/COUNTRY
1.4 MARKET INVESTMENT SCENARIO STRATEGIC
1.5 MARKET ANALYSIS BY TYPE (USD MILLION)
1.6 MARKET ANALYSIS BY APPLICATION (USD MILLION)
2.1 DRIVER, RESTRAINT, CHALLENGE AND OPPORTUNITIES ANALYSIS
2.1.1 MARKET DRIVER ANALYSIS
2.1.2 MARKET RESTRAINT ANALYSIS
2.1.3 MARKET OPPORTUNITY
2.1.4 MARKET CHALLENGES
3.1 INDUSTRY TRENDS
3.1.1 SWOT ANALYSIS
3.1.2 PESTEL ANALYSIS
3.1.3 PORTER’S FIVE FORCES ANALYSIS
3.2 POTENTIAL MARKET AND GROWTH POTENTIAL ANALYSIS
4.1 COVID-19 ANALYSIS
5.1 GLOBAL THERAPEUTIC DRUGS FOR GASTROINTESTINAL CANCER MARKET, SALES AREA, TYPE
5.2 MERGERS & ACQUISITIONS, PARTNERSHIPS, PRODUCT LAUNCH, AND COLLABORATION IN GLOBAL THERAPEUTIC DRUGS FOR GASTROINTESTINAL CANCER MARKET
7.1 GLOBAL THERAPEUTIC DRUGS FOR GASTROINTESTINAL CANCER MARKET SIZE AND SHARE (2017 - 2031) (USD MILLION)
8.1 GLOBAL THERAPEUTIC DRUGS FOR GASTROINTESTINAL CANCER MARKET SIZE AND SHARE BY TYPE (2017 - 2023) (USD MILLION)
8.2 GLOBAL THERAPEUTIC DRUGS FOR GASTROINTESTINAL CANCER MARKET SIZE AND SHARE BY TYPE (2025 - 2031) (USD MILLION)
9.1 GLOBAL THERAPEUTIC DRUGS FOR GASTROINTESTINAL CANCER MARKET SIZE AND SHARE BY APPLICATION (2017 - 2023) (USD MILLION)
9.2 GLOBAL THERAPEUTIC DRUGS FOR GASTROINTESTINAL CANCER MARKET SIZE AND SHARE BY APPLICATION (2025 - 2031) (USD MILLION)
10.1 GLOBAL THERAPEUTIC DRUGS FOR GASTROINTESTINAL CANCER MARKET SIZE AND SHARE BY REGION (2017 - 2023) (USD MILLION)
10.2 GLOBAL THERAPEUTIC DRUGS FOR GASTROINTESTINAL CANCER MARKET SIZE AND SHARE BY REGION (2025 - 2031) (USD MILLION)
11.1 NORTH AMERICA THERAPEUTIC DRUGS FOR GASTROINTESTINAL CANCER MARKET SIZE AND SHARE BY COUNTRY (2017 - 2023) (USD MILLION)
11.2 NORTH AMERICA THERAPEUTIC DRUGS FOR GASTROINTESTINAL CANCER MARKET SIZE AND SHARE BY COUNTRY (2025 - 2031) (USD MILLION)
11.3 NORTH AMERICA THERAPEUTIC DRUGS FOR GASTROINTESTINAL CANCER MARKET SIZE AND SHARE BY TYPE (2017 - 2023) (USD MILLION)
11.4 NORTH AMERICA THERAPEUTIC DRUGS FOR GASTROINTESTINAL CANCER MARKET SIZE AND SHARE BY TYPE (2025 - 2031) (USD MILLION)
11.5 NORTH AMERICA THERAPEUTIC DRUGS FOR GASTROINTESTINAL CANCER MARKET SIZE AND SHARE BY APPLICATION (2017 - 2023) (USD MILLION)
11.6 NORTH AMERICA THERAPEUTIC DRUGS FOR GASTROINTESTINAL CANCER MARKET SIZE AND SHARE BY APPLICATION (2025 - 2031) (USD MILLION)
12.1 EUROPE THERAPEUTIC DRUGS FOR GASTROINTESTINAL CANCER MARKET SIZE AND SHARE BY COUNTRY (2017 - 2023) (USD MILLION)
12.2 EUROPE THERAPEUTIC DRUGS FOR GASTROINTESTINAL CANCER MARKET SIZE AND SHARE BY COUNTRY (2025 - 2031) (USD MILLION)
12.3 EUROPE THERAPEUTIC DRUGS FOR GASTROINTESTINAL CANCER MARKET SIZE AND SHARE BY TYPE (2017 - 2023) (USD MILLION)
12.4 EUROPE THERAPEUTIC DRUGS FOR GASTROINTESTINAL CANCER MARKET SIZE AND SHARE BY TYPE (2025 - 2031) (USD MILLION)
12.5 EUROPE THERAPEUTIC DRUGS FOR GASTROINTESTINAL CANCER MARKET SIZE AND SHARE BY APPLICATION (2017 - 2023) (USD MILLION)
12.6 EUROPE THERAPEUTIC DRUGS FOR GASTROINTESTINAL CANCER MARKET SIZE AND SHARE BY APPLICATION (2025 - 2031) (USD MILLION)
13.1 ASIA PACIFIC THERAPEUTIC DRUGS FOR GASTROINTESTINAL CANCER MARKET SIZE AND SHARE BY COUNTRY (2017 - 2023) (USD MILLION)
13.2 ASIA PACIFIC THERAPEUTIC DRUGS FOR GASTROINTESTINAL CANCER MARKET SIZE AND SHARE BY COUNTRY (2025 - 2031) (USD MILLION)
13.3 ASIA PACIFIC THERAPEUTIC DRUGS FOR GASTROINTESTINAL CANCER MARKET SIZE AND SHARE BY TYPE (2017 - 2023) (USD MILLION)
13.4 ASIA PACIFIC THERAPEUTIC DRUGS FOR GASTROINTESTINAL CANCER MARKET SIZE AND SHARE BY TYPE (2025 - 2031) (USD MILLION)
13.5 ASIA PACIFIC THERAPEUTIC DRUGS FOR GASTROINTESTINAL CANCER MARKET SIZE AND SHARE BY APPLICATION (2017 - 2023) (USD MILLION)
13.6 ASIA PACIFIC THERAPEUTIC DRUGS FOR GASTROINTESTINAL CANCER MARKET SIZE AND SHARE BY APPLICATION (2025 - 2031) (USD MILLION)
14.1 LATIN AMERICA THERAPEUTIC DRUGS FOR GASTROINTESTINAL CANCER MARKET SIZE AND SHARE BY COUNTRY (2017 - 2023) (USD MILLION)/p>
14.2 LATIN AMERICA THERAPEUTIC DRUGS FOR GASTROINTESTINAL CANCER MARKET SIZE AND SHARE BY COUNTRY (2025 - 2031) (USD MILLION)
14.3 LATIN AMERICA THERAPEUTIC DRUGS FOR GASTROINTESTINAL CANCER MARKET SIZE AND SHARE BY TYPE (2017 - 2023) (USD MILLION)
14.4 LATIN AMERICA THERAPEUTIC DRUGS FOR GASTROINTESTINAL CANCER MARKET SIZE AND SHARE BY TYPE (2025 - 2031) (USD MILLION)
14.5 LATIN AMERICA THERAPEUTIC DRUGS FOR GASTROINTESTINAL CANCER MARKET SIZE AND SHARE BY APPLICATION (2017 - 2023) (USD MILLION)
14.6 LATIN AMERICA THERAPEUTIC DRUGS FOR GASTROINTESTINAL CANCER MARKET SIZE AND SHARE BY APPLICATION (2025 - 2031) (USD MILLION)
15.1 MIDDLE EAST & AFRICA THERAPEUTIC DRUGS FOR GASTROINTESTINAL CANCER MARKET SIZE AND SHARE BY COUNTRY (2017 - 2023) (USD MILLION)
15.2 MIDDLE EAST & AFRICA THERAPEUTIC DRUGS FOR GASTROINTESTINAL CANCER MARKET SIZE AND SHARE BY COUNTRY (2025 - 2031) (USD MILLION)
15.3 MIDDLE EAST & AFRICA THERAPEUTIC DRUGS FOR GASTROINTESTINAL CANCER MARKET SIZE AND SHARE BY TYPE (2017 - 2023) (USD MILLION)
15.4 MIDDLE EAST & AFRICA THERAPEUTIC DRUGS FOR GASTROINTESTINAL CANCER MARKET SIZE AND SHARE BY TYPE (2025 - 2031) (USD MILLION)
15.5 MIDDLE EAST & AFRICA THERAPEUTIC DRUGS FOR GASTROINTESTINAL CANCER MARKET SIZE AND SHARE BY APPLICATION (2017 - 2023) (USD MILLION)
15.6 MIDDLE EAST & AFRICA THERAPEUTIC DRUGS FOR GASTROINTESTINAL CANCER MARKET SIZE AND SHARE BY APPLICATION (2025 - 2031)< (USD MILLION)/p>
16.1 Amgen & Amgen Ireland
16.1.1 COMPANY DETAILS
16.1.2 FINANCIALS (USD MILLION)
16.1.3 PRODUCT SUMMARY
16.1.4 RECENT DEVELOPMENTS
16.2 Bristol-Myers Squibb Company
16.3 Roche
16.4 Eli Lilly and Company
16.5 Johnson & Johnson Private
16.6 GlaxoSmithKline
16.7 Celgene Corporation
16.8 Pfizer
16.9 Sanofi
16.10 Novartis
18.1 METHODOLOGY
18.2 RESEARCH DATA SOURCE
18.2.1 SECONDARY DATA
18.2.2 KEY DATA FROM SECONDARY
18.2.3 PRIMARY DATA
18.2.4 KEY DATA FROM PRIMARY
18.2.5 INDUSTRY INSIGHT FROM PROFESSIONAL LEADERS
18.2.6 MARKET ESTIMATION
18.2.7 MARKET ESTIMATION: TOP-DOWN AND BOTTOM-UP APPROACH
18.2.8 LEGAL DISCLAIMER
Market Segments
By TypeOncology Department
Radiology Department
other
By Application
hospital
Specialized cancer treatment center
clinic
Outpatient Surgery Center
Companies
Amgen & Amgen Ireland
Bristol-Myers Squibb Company
Roche
Eli Lilly and Company
Johnson & Johnson Private
GlaxoSmithKline
Celgene Corporation
Pfizer
Sanofi
Novartis
BROWSE INDUSTRY
- PROACTIVE
- QUALITY & RELIABILITY
- GLOBAL OUTREACH
- COMPETITIVE PRICING
WHY CHOOSE US
We manage our resources 24/7 to identify issues and address them before they become problems.
We are committed to providing reliable and highly accurate data with an excellent quality control system.
6 Major regions and 40+ countries level analysis accomplished.
Our pricing strategy is highly competitive in the market, without compensating on the quality and the timeline of project delivery.